542 related articles for article (PubMed ID: 23721881)
1. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ; Zhou X; Mitch WE; Goldberg AL
Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
3. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
4. Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease.
Chen JL; Walton KL; Hagg A; Colgan TD; Johnson K; Qian H; Gregorevic P; Harrison CA
Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5266-E5275. PubMed ID: 28607086
[TBL] [Abstract][Full Text] [Related]
5. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
Glass DJ
Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
7. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
8. Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle.
Smith IJ; Aversa Z; Alamdari N; Petkova V; Hasselgren PO
J Cell Biochem; 2010 Nov; 111(4):1059-73. PubMed ID: 20677217
[TBL] [Abstract][Full Text] [Related]
9. Activin A induces skeletal muscle catabolism via p38β mitogen-activated protein kinase.
Ding H; Zhang G; Sin KW; Liu Z; Lin RK; Li M; Li YP
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):202-212. PubMed ID: 27897407
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease.
Verzola D; Barisione C; Picciotto D; Garibotto G; Koppe L
Kidney Int; 2019 Mar; 95(3):506-517. PubMed ID: 30598193
[TBL] [Abstract][Full Text] [Related]
11. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies.
Martin A; Gallot YS; Freyssenet D
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1150-1167. PubMed ID: 36864755
[TBL] [Abstract][Full Text] [Related]
13. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
14. Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins.
Lokireddy S; Mouly V; Butler-Browne G; Gluckman PD; Sharma M; Kambadur R; McFarlane C
Am J Physiol Cell Physiol; 2011 Dec; 301(6):C1316-24. PubMed ID: 21900687
[TBL] [Abstract][Full Text] [Related]
15. Development of novel activin-targeted therapeutics.
Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
[TBL] [Abstract][Full Text] [Related]
16. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome.
Sandri M
Int J Biochem Cell Biol; 2013 Oct; 45(10):2121-9. PubMed ID: 23665154
[TBL] [Abstract][Full Text] [Related]
17. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
18. Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Ma H; Pierre P; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jan; 304(1):E41-50. PubMed ID: 23115080
[TBL] [Abstract][Full Text] [Related]
19. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.
Winbanks CE; Murphy KT; Bernardo BC; Qian H; Liu Y; Sepulveda PV; Beyer C; Hagg A; Thomson RE; Chen JL; Walton KL; Loveland KL; McMullen JR; Rodgers BD; Harrison CA; Lynch GS; Gregorevic P
Sci Transl Med; 2016 Jul; 8(348):348ra98. PubMed ID: 27440729
[TBL] [Abstract][Full Text] [Related]
20. The regulation of muscle protein turnover in diabetes.
Workeneh B; Bajaj M
Int J Biochem Cell Biol; 2013 Oct; 45(10):2239-44. PubMed ID: 23838169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
